Pfizer Inc - Digital Transformation Strategies

Pfizer Inc - Digital Transformation Strategies

Summary

This report provides insight into Pfizer's tech activities, including its digital transformation strategies, its innovation programs, its technology initiatives, its estimated ICT budget, and its major ICT contracts.

Pfizer Inc (Pfizer) discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, women’s health, cancer, inflammation, immune disorders, and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa, and the Middle East. Pfizer is headquartered in New York, the US.

In January 2020, Pfizer launched its Center of Excellence Network for Vaccine Research, a global program focused on collaborating with academic institutions to conduct research on epidemiology to identify diseases that can be cured through vaccines, as well as measure its effectiveness on adults. Pfizer’s vaccine division opened its first Center of Excellence at the University of Louisville.

Pfizer Blockchain Center of Excellence through its open innovation workshop has formed an initiative called the Clinical Supply Blockchain Working Group (CSBWG) that focuses on developing an interoperable, transparent, and auditable blockchain based platform to enhance trial supply chain and experimental drug tracking. The working group comprises of companies, such as AstraZeneca, GlaxoSmithKline, Merck, Deloitte, Biogen, LedgerDomain, and Pfizer.

Scope

• Pfizer adopted AI as its core technology for conducting trials, processing vaccines, and streamlining distribution. Pfizer's investment in digital infrastructure, digitalization of R&D operations, and AI-enabled working systems further complemented its effort in producing and distributing vaccines. Using AI technology in many phases of vaccine making and testing enabled Pfizer to roll out vaccines sooner, helping meet public’s immediate needs during initial onslaught of the global pandemic.
• Pfizer is adopting technologies, such as AI and analytics, for accelerating drug discovery process and to increase its efficiency. Pfizer is deploying AI technologies for streamlining its drug development. Pfizer tested a collaborative deep learning and analytics platform, dubbed Cortex, for automatic categorization of drug particle shapes. Pfizer is adopting advanced data mining techniques to glean useful insights from its existing clinical trial data, which help company discover hidden patterns, design new trials, identify new ways of utilizing existing drugs, and evaluate the effectiveness of drugs.
• Pfizer has rolled out various accelerator and innovation programs, including Centers of Excellence Network for Vaccine Research and Real-World Evidence; Digital Research Hubs; Pfizer Blockchain Center of Excellence; and Pfizer Innovation Research (PfIRe) Lab, to encourage start-ups, innovators, and employees. Pfizer is also involved in Project Catalyst, an external research initiative started by the AARP and other partners, including UnitedHealthcare and Georgia Tech, focusing on digital R&D to promote consumer-friendly innovation for elderly users.

Reasons to Buy

• Gain insights into Pfizer's tech operations.
• Gain insights into its tech strategies and innovation initiatives.
• Gain insights into its technology themes under focus.
• Gain insights into various product launches, partnerships, investments and acquisition strategies.